For research use only. Not for use in humans.

Lifastuzumab vedotin

Synonyms: LIFA, DNIB0600A, RG-7599

Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.

Lifastuzumab vedotin

CAS No. 1401812-88-1

Click to purchase products related to Lifastuzumab vedotin

Quality Control

Batch: D401001 Purity: 99% Protein concentration: 8.79mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation Sodium Channel Others
A-803467 2
Camostat Mesilate 16
Ambroxol HCl 0
Flecainide hydrochloride 0
Suzetrigine 0
Tenapanor 0
SEA0400 0 ROS,ERK,p38 MAPK
SLC13A5-IN-1 0
LTGO-33 0
EIPA 8
Vernakalant (RSD1235) Hydrochloride 0
QX-314 chloride 0
VX-150 0
Rimeporide 0
(-)-Sparteine Sulfate 0
Benzocaine 0
Tolperisone HCl 1
Vinpocetine 1
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer.
References

Product Details

CAS No. 1401812-88-1
ADC antiody Lifastuzumab
ADC cytotoxin MMAE
Formulation 0.1 MPro-Ac,0.02 MArg-Ac,pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.